ImmunityBio Tidigare resultatutveckling
Tidigare kriterier kontrolleras 0/6
ImmunityBio s intäkter har minskat med en genomsnittlig årlig takt på -10.4%, medan Biotechs -branschen såg intäkter på växande 33.8% årligen. Intäkterna har varit växande med en genomsnittlig takt på 89.8% per år.
Viktig information
-10.42%
Tillväxttakt i vinsten
8.12%
Tillväxttakt för EPS
| Biotechs Tillväxt i branschen | 17.04% |
| Intäkternas tillväxttakt | 89.84% |
| Avkastning på eget kapital | n/a |
| Nettomarginal | -606.15% |
| Senaste uppdateringen av resultatet | 31 Mar 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Seeking Alpha • 13h
ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout
Summary ImmunityBio is transitioning into a scalable bladder cancer immunotherapy platform, driven by accelerating Anktiva adoption and robust revenue growth. 1Q26 revenue surged 168% YoY to $44.2M, with strong physician uptake, but operating expenses and adjusted net loss ($86.2M) remain elevated amid heavy investment. The papillary sBLA for Anktiva is a key near-term catalyst; regulatory uncertainty persists, but compelling QUILT-3.032 data and prior FDA approval in CIS support optimism. The Tokyo-172 BCG deal positions IBRX to resolve U.S. supply bottlenecks, enabling dual-source BCG infrastructure and global expansion, enhancing platform value. Read the full article on Seeking AlphaAnalysartikel • May 11
Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results
Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...
Ny berättelse • Apr 01
Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power
Catalysts About ImmunityBio ImmunityBio is a clinical stage immunotherapy company focused on using its IL-15 based ANKTIVA platform, natural killer cell therapies, and DNA vaccine vectors to treat cancer and immune related conditions. What are the underlying business or industry changes driving this perspective?
Ny berättelse • Mar 18
Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential
Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?
Ny berättelse • Mar 04
Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects
Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?Analysartikel • Aug 07
Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
NasdaqGS:IBRX 1 Year Share Price vs Fair Value Explore ImmunityBio's Fair Values from the Community and select yours A...Seeking Alpha • Apr 29
ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
Summary ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings. Long-term optimism persists for IBRX stock due to Anktiva's "best-in-class" data and potential for significant market cap growth, despite immediate financial challenges. Read the full article on Seeking AlphaSeeking Alpha • Mar 07
ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
Summary ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC. Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. Read the full article on Seeking AlphaSeeking Alpha • Jan 17
ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval
Summary ImmunityBio, Inc.'s Anktiva, approved for bladder cancer, shows promise for expansion into other solid tumors, with key trials ongoing in lung and colorectal cancers. Financial challenges persist, but recent product sales and supportive financing extend the cash runway, providing a potential growth opportunity. Strengths include data supporting new approvals and expanding Anktiva's market, though risks involve unclear lung cancer market size and significant liabilities. Upgrading IBRX stock to “Buy” due to likely 2025 catalysts: accelerating Anktiva sales, potential lung cancer approval, and expanding bladder cancer market. Read the full article on Seeking AlphaSeeking Alpha • Dec 11
ImmunityBio's Cash Burn And Dilution Dampen Anktiva's Potential
Summary Anktiva received FDA approval in April 2024 for BCG-unresponsive NMIBC. Q3 revenue was $5.954 million, but high R&D and SG&A expenses led to an $80.253 million operational loss, with notable share dilution. Financial health shows a current ratio over 2.0, but high long-term debt and a $34 million monthly cash burn raise concerns. ImmunityBio is conducting trials of Anktiva in various cancers, including NSCLC and ovarian cancer. IBRX remains a "sell" due to ongoing dilution, financial risks, and limited upside despite Anktiva's potential in NMIBC. Read the full article on Seeking AlphaSeeking Alpha • Oct 25
ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful
Summary ImmunityBio's Anktiva shows promise in cancer immunotherapy, with initial sales of $900K and ongoing studies in various cancers, including non-small cell lung cancer. Despite high debt and cash burn, friendly debt terms from entities connected to the founder mitigate financial risks, maintaining shareholder value. The company's novel platforms, like the CD19 t-haNK therapy, diversify its pipeline, reducing reliance on Anktiva alone for future growth. While IBRX has significant upside potential, any negative news could deflate the stock's hype-driven valuation, making it a high-risk investment. Read the full article on Seeking AlphaSeeking Alpha • Oct 07
ImmunityBio: Moving The Needle
Summary ImmunityBio's ANKTIVA shows promising commercial and clinical progress, with expanded patient access and potential EU/UK regulatory filings, enhancing its global market penetration and revenue prospects. Recent positive clinical data for ANKTIVA in NSCLC and endometrial cancer trials highlight its potential beyond bladder cancer, boosting its long-term growth outlook. Despite significant advancements, risks include regulatory hurdles, commercialization challenges, high cash burn, and reliance on founder Dr. Patrick Soon-Shiong for funding. I plan to capitalize on the current sell-off, placing buy orders around $3.50-$4.00, and setting sell targets at $9 and $12.25 per share. Read the full article on Seeking AlphaSeeking Alpha • Sep 21
ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt
Summary Anktiva, ImmunityBio's lead molecule, shows promising results with a 71% CR rate and 100% survival at 24 months for BCG-unresponsive NMIBC. Despite Anktiva's potential, ImmunityBio faces financial challenges, relying heavily on loans from founder Dr. Soon-Shiong, leading to high indebtedness. The company has a market cap of $2.43bn but limited cash runway, raising concerns about its financial stability and lack of recent earnings calls. Anktiva's competitive position in a diversified NMIBC market is strong, but the financial entanglement with Dr. Soon-Shiong poses significant risks for retail investors. Read the full article on Seeking AlphaFördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur ImmunityBio tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Mar 26 | 141 | -855 | 163 | 238 |
| 31 Dec 25 | 113 | -351 | 150 | 219 |
| 30 Sep 25 | 83 | -349 | 158 | 185 |
| 30 Jun 25 | 57 | -367 | 157 | 185 |
| 31 Mar 25 | 31 | -409 | 159 | 186 |
| 31 Dec 24 | 15 | -414 | 169 | 190 |
| 30 Sep 24 | 7 | -588 | 165 | 202 |
| 30 Jun 24 | 1 | -598 | 161 | 199 |
| 31 Mar 24 | 0 | -601 | 144 | 201 |
| 31 Dec 23 | 1 | -583 | 130 | 232 |
| 30 Sep 23 | 1 | -458 | 129 | 232 |
| 30 Jun 23 | 1 | -473 | 117 | 256 |
| 31 Mar 23 | 1 | -430 | 101 | 266 |
| 31 Dec 22 | 0 | -417 | 109 | 242 |
| 30 Sep 22 | 1 | -400 | 93 | 241 |
| 30 Jun 22 | 1 | -376 | 103 | 218 |
| 31 Mar 22 | 1 | -370 | 119 | 209 |
| 31 Dec 21 | 1 | -347 | 127 | 192 |
| 30 Sep 21 | 0 | -323 | 124 | 186 |
| 30 Jun 21 | 0 | -301 | 112 | 174 |
| 31 Mar 21 | 1 | -264 | 97 | 154 |
| 31 Dec 20 | 1 | -222 | 61 | 140 |
| 30 Sep 20 | 2 | -176 | 56 | 110 |
| 31 Dec 19 | 2 | -158 | 46 | 112 |
| 31 Dec 18 | 3 | -84 | 29 | 47 |
Kvalitetsintäkter: IBRX är för närvarande olönsam.
Växande vinstmarginal: IBRX är för närvarande olönsam.
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: IBRX är olönsam och förlusterna har ökat under de senaste 5 åren i en takt av 10.4% per år.
Accelererande tillväxt: Det går inte att jämföra IBRX s intäktstillväxt under det senaste året med dess 5-åriga genomsnitt eftersom det för närvarande är olönsamt
Resultat vs industri: IBRX är olönsam, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Biotechs branschen ( 43% ).
Avkastning på eget kapital
Hög ROE: IBRX s skulder överstiger dess tillgångar, så det är svårt att beräkna dess avkastning på eget kapital.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/20 05:11 |
| Aktiekurs vid dagens slut | 2026/05/20 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
ImmunityBio, Inc. bevakas av 8 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |
| Jason Kolbert | D. Boral Capital LLC. |